POWERSAFETYTRUST
2 0 0 M I L L I O N V A C C I N A T I O N S O V E R 2 0 Y E A R S
IT’SALLABOUT
TRUST
POWERSAFETYTRUST
2 0 0 M I L L I O N V A C C I N A T I O N S O V E R 2 0 Y E A R S
IT’SALLABOUT
TRUSTIT’S
TRUS
BROAD ERYSIPELAS PROTECTION• Against all most common swine Erysipelas strains, 1a, 1b and 2
• Erysipelas may appear in:
– acute form: septicaemia, hyperthermia, anorexia, erythema and death
– sub acute /chronic forms: arthritis, endocarditis and orchitis
– indirect reproductive failure: return to heat, abortions, embryonic
death, infertility and decreased seminal quality
PARVOVIRUS PROTECTION • Against all strains of PPV causing reproductive problems to date
• Porcine parvovirus (PPV) is the major cause of reproductive failure in swine = SMEDI (stillbirth, mummi� cation, embryonic death and infertility)
• Piglets born viremic during infection
for broad and strong protection against Parvovirus and Erysipelas
VACCINATION IS THE ONLY WAY TO CONTROL THE DISEASES
38.3
38.6
38.9
39.2
39.5
D2D1D0+6hD0*
0
10
20
30
40
50
60
D2D1Day 0+6 h
(ºC)
(%)
a
a
bb
a
b b
a
b
b
a
aa
a
b
b a
a
bab
a
a, b : Values in same column holding di�erent superscripts are showing signi�cant di�erence (p<0.05)* Temperature on day 0 was used to covariate the rest of the temperature analysis
a, b : Values in same column holding di�erent superscripts are showing signi�cant di�erence (p<0.05)
Vaccine B
Vaccine A
PARVORUVAX
Vaccine B
Vaccine A
PARVORUVAX
A proper diagnosis of Parvo and Erysipelas is crucialDiagnosis of Parvovirus• Increased percentage of mummies, irregular returns
or decreased litter size, primarily in gilts, is suggestive of PPV infection
• PPV antigen in the lungs or liver of mummifi ed fetuses can be con� rmed using immuno� uorescence or PCR
• Paired serology of samples from gilts and sows can indicate the infection
Diagnosis of Erysipelas • High temperature and the diamond shaped skin
lesions are typical for the acute clinical disease
• Post-mortems, culture of the organism and /or PCR from the sudden deaths con� rms the diagnosis
• Paired serology using Hemagglutination Inhibition Test or ELISA can con� rm the exposure to the germ in sows or pigs
for broad and strong protection against Parvovirus and Erysipelas
Proven safety demonstrated in research and � eld experience over more than 20 years3 groups of sows were vaccinated with di� erent P+E vaccines (Morillo et al., IPVS 2010, 863)
38.3
38.6
38.9
39.2
39.5
D2D1D0+6hD0*
0
10
20
30
40
50
60
D2D1Day 0+6 h
(ºC)
(%)
a
a
bb
a
b b
a
b
b
a
aa
a
b
b a
a
bab
a
a, b : Values in same column holding di�erent superscripts are showing signi�cant di�erence (p<0.05)* Temperature on day 0 was used to covariate the rest of the temperature analysis
a, b : Values in same column holding di�erent superscripts are showing signi�cant di�erence (p<0.05)
Vaccine B
Vaccine A
PARVORUVAX
Vaccine B
Vaccine A
PARVORUVAX
VACCINATION IS THE ONLY WAY TO CONTROL THE DISEASES
: Safety
A VACCINE WITH AN EXCELLENT SAFETY PROFILE
38.3
38.6
38.9
39.2
39.5
D2D1D0+6hD0*
0
10
20
30
40
50
60
D2D1Day 0+6 h
(ºC)
(%)
a
a
bb
a
b b
a
b
b
a
aa
a
b
b a
a
bab
a
a, b : Values in same column holding di�erent superscripts are showing signi�cant di�erence (p<0.05)* Temperature on day 0 was used to covariate the rest of the temperature analysis
a, b : Values in same column holding di�erent superscripts are showing signi�cant di�erence (p<0.05)
Vaccine B
Vaccine A
PARVORUVAX
Vaccine B
Vaccine A
PARVORUVAX
Development of systemic reactions
Development of injection site reactions
induces both cell mediated and humoral immunity
Speci� c protective Cell Mediated Immunity
CMI is… CLEANING OUT INFECTION• mediated by IFNγ secreting cells (IFNγ-SC)
• measured in ELISPOT test
IL-4
IL-12
TH1 TH2
NK cells, TH2 cells,mast cells
RegulatoryTH2 cells
Eosinophilgrowth and
di�erentiaton
Mast-cellgrowth
B cell
IFN-γ
IFN-γ IFN-γ
IFN-γ
IFN-γ
IL-2
IL-12
IL-12IL-12
IL-4, IL-10
IL-5IL-3IL-4IL-10
IL-4 IL-5 IL-6IL-13
IL-4 IL-10IL-13
IL-18
IL-2TNF-β
TNF-βTNF-β
IFN-γ
Macrophageactivation
TCactivation
B cell
IgG2aIgM
IGG1 IGA IGE
NA + …
RegulatoryTH2 cells
IL-4
Macrophages
CMI
KILLS
Tc
PPV speci� c cytotoxic T-cellskill PPV infected cells
Erysipelas speci� c macrophage activation & SpaA facilitated kill
IFN-
IL-12
Zeeuw et al., J Gen Virol 88 (2007) 420-27; Joswik et al., J Gen Virol 90 (2009) 2437-41; A.L. Ingebritson, Th esis ISU 2009; Crussard et al., IPVS/ESPHM 2016, 259; Chae et al., Vet J 194 (2012) 151-157
Th e critical measures for DUAL PARVO AND ERY VACCINE PROTECTION are NA, Anti-SpaA & IFNγ-SC
Speci� c protective humoral immune response
Humoral immunity is… PROTECTING AGAINST EFFECT OF INFECTION
• mediated by small fractions of speci� c antibodies
• Erysipelas type 1a, 1b and 2Anti-SpaA – a specifi c opsonizing antibodymeasured by SpaA ELISA
• PPVneutralizing antibodies (NA) measured by serum neutralization test
induces both cell mediated and humoral immunity
IL-4
IL-12
TH1 TH2
NK cells, TH2 cells,mast cells
RegulatoryTH2 cells
Eosinophilgrowth and
di�erentiaton
Mast-cellgrowth
B cell
IFN-γ
IFN-γ IFN-γ
IFN-γ
IFN-γ
IL-2
IL-12
IL-12IL-12
IL-4, IL-10
IL-5IL-3IL-4IL-10
IL-4 IL-5 IL-6IL-13
IL-4 IL-10IL-13
IL-18
IL-2TNF-β
TNF-βTNF-β
IFN-γ
Macrophageactivation
TCactivation
B cell
IgG2aIgM
IGG1 IGA IGE
NA + …
RegulatoryTH2 cells
IL-4
Macrophages
Humoral
Erysipelas Speci� c Anti-SpaA inhibits bacterial action & facilitates phagocytosis
PPV speci� c NA blocks receptor contact & virus uptake
Humoral immunity is… PROTECTING AGAINST PROTECTING AGAINST EFFECT OF INFECTION EFFECT OF INFECTION
• mediated by small fractions of speci� c antibodies
• Erysipelas type 1a, 1b and 2Anti-SpaA – a specifi c opsonizing antibodymeasured by SpaA ELISAmeasured by SpaA ELISAmeasured by
• PPVneutralizing antibodies (NA) measured by serum neutralization test
TH2
RegulatoryTH2 cells
Eosinophilgrowth and
di�erentiaton
Mast-cellgrowth
B cell
IFN-γ
IL-12
IL-4, IL-10
IL-5IL-3IL-4IL-10
IL-4 IL-4 IL-5 IL-5 IL-6 IL-6IL-13
IL-4 IL-4IL-12 IL-4IL-12 IL-10IL-13
TNF-β
IgM
IGA IGE
NA + …
IgMIGG1IgM
IGA
Erysipelas Speci� c Anti-SpaA inhibits bacterial action & facilitates phagocytosis
PPV speci� c NA blocks receptor contact & virus uptake
Zeeuw et al., J Gen Virol 88 (2007) 420-27; Joswik et al., J Gen Virol 90 (2009) 2437-41; A.L. Ingebritson, Th esis ISU 2009; Crussard et al., IPVS/ESPHM 2016, 259; Chae et al., Vet J 194 (2012) 151-157 No correlation exists to general IgG ELISA s or HI tests
Th e critical measures for DUAL PARVO AND ERY VACCINE PROTECTION are NA, Anti-SpaA & IFNγ-SC
Th evenon et al., IPVS 2002, 561
8
6
4
2
047 49 51 53
Time (day)
Aver
age
daily
sym
ptom
scor
e
55 57 59
PARVORUVAX
1:10 Ery Ag vac.
1:100 Ery Ag vac.
Placebo
14
12
10
8
6
4
2
0
Mea
n fe
tuse
s num
ber
Unvaccinated
FETUSES VIABILITY IN UNVACCINATED AND VACCINATED GILTS
Vaccinated
Alive fetusesDead fetusesMummies
12.8born alive
2.1born alive
Joisel et al., IPVS 2004, 430
GIVES e�cient protection
Joisel et al.,
8
6
4
2
047 49 51 53
Time (day)
Aver
age
daily
sym
ptom
scor
e
55 57 59
PARVORUVAX
1:10 Ery Ag vac.
1:100 Ery Ag vac.
Placebo
PROVIDES POWERFUL AND BROAD DUAL PROTECTION AGAINST PARVOVIRUS AND ERYSIPELAS
Parvo e� cacy trialFoetus viability in unvaccinated and Parvoruvax vaccinated gilts
Erysipelas e� cacy trial Mean daily clinical score per group Challenge at day 50 with serotype 1 and 2 strains
: Conclusionon immune response
Th evenon et al., IPVS 2002, 561
GIVES e�cient protection
POWERSAFETYTRUSTPOWER
IFNγ-SC/CMI – a signi� cant and persistent cell mediated immune response against PPV and Erysipelas(Juillard et al., IPVS 2006, 162. Piras et al., IPVS 2006,160)
Neutralizing Antibodies – a powerful and long lasting protective humoral immune response against PPV (Brun et al., IPVS 2006,161)
Anti-SpaA Antibodies – a very quick and strong protective humoral immune response against Erysipelas• Even following � rst primo vaccination
• Specifi c Anti-SpaA antibodies as well as neutralizing antibodiesare linked directly to protection
• Poor correlation to general Ig tests like HI & ELISA
• Commercial ELISA’s are designed on various antigens to discover previous � eld infection.
(Crussard et al., IPVS/ESPHM 2016, 259)
Erysipelas e� cacy trial Mean daily clinical score per group Challenge at day 50 with serotype 1 and 2 strains
Primo vaccination Booster
SOWS AND GILTS
2 doses with a 3- to 4-week interval,
the second dose given at least 2 weeks before mating
At least 1 week before each mating
or 1 dose every six month
BOARS Vaccination twice with 3 weeks interval Every 6 months
Antib
odie
s
Age of giltsEntry in quarantine
INEFFICIENTVACCINATION
150 days5 months
180 days6 months
EFFICIENTVACCINATION
: vaccination scheme
Ceva Santé Animale S.A. - 10, av. de La Ballastière - 33500 Libourne - France - Phone: 00 33 (0) 5 57 55 40 40 - Fax: 00 33 (0) 5 57 55 42 37 - www.ceva.com - [email protected]
Cré
dit
ph
oto
: fo
tolia
.co
m
E F F IC AC Y & SA F E T YS OW & B OA R PRO T E C T IONL E A DI NG E X PE R I E NC E T H ROUG H 2 0 Y E A R S I N S O W S A N D G I L T S
POWERSAFETYTRUST
Parvoruvax® Suspension for Injection contains Inactivated Porcine Parvovirus (K-22 strain) and Erysipelothrix rhusiopathiae (lysed bacterial cells), serotype 2. Also contains aluminium hydroxide and thiomersal. The product is indicated for active immunisation of breeding pigs (sows, gilts and boars) against porcine parvovirosis, to reduce the number of stillbirths and mummi� ed piglets, and against erysipelas to reduce or prevent clinical symptoms. Vaccination can occasionally cause reactions of hypersensitivity in some animals, particularly in those animals sensitised by the erysipelas infection. In such case, appropriate treatment such as adrenaline should be provided. Rarely, vaccination can induce a small local reaction (<1.5 cm) at the site of injection without any e� ect on the health or productivity of the animal. The vaccination can cause a slight rise in body temperature (<0.2°C) that returns to normal values from 1 to 2 days after vaccination without any consequence to the health or productivity of the animal. Primary vaccination against porcine parvovirosis should not be carried out in the presence of maternally derived antibodies. Only healthy animals should be vaccinated. The vaccine is safe for use during pregnancy and lactation. However, avoid vaccination during the 3 weeks following service mating. Withdrawal periods: Zero days. Pharmaceutical precautions: Use immediately after opening. Store between 2°C and 8°C, protected from light. For more details, see the SPC applicable in your country.This page contains information on a veterinary biological product sold in several di� erent countries and areas where it may be subject to di� erent regulatory approvals. Ceva gives no guarantee that the details presented are correct with respect to all locations. In addition, the safety and e� cacy data and the withholding periods may be di� erent depending on local regulations. Please consult your veterinarian for further information.